Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: A meta-analysis

Human Immunology

Volumn 75, Issue 12, 2014, Pages 1268-1275

  Zhang, Ling ^a   Lu, Qian ^a   Yang, Zhiqing ^a   Wang, Xiaojun ^a   Cai, Lei ^a   Liu, Xiangde ^a   Liao, Rui ^a   Yang, Xing ^b   Chen, Yinzhi ^c   Yang, Zhanyu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b 324 hospital of people s liberation army   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Interleukin 28B; Liver transplantation; Single nucleotide polymorphisms; Sustained virological response

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; INTERLEUKIN 28B; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; CAUCASIAN; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; ALLOTRANSPLANTATION; GENETICS; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; LIVER; META ANALYSIS; RECURRENT DISEASE; VIROLOGY;

ANTIVIRAL AGENTS; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84925301009     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.09.005     Document Type: Article

References (39)

1. Adam R., McMaster P., O'Grady J.G., Castaing D., Klempnauer J.L., Jamieson N., et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003, 9:1231.
2. Terrault N.A., Shiffman M.L., Lok A.S., Saab S., Tong L., Brown R.S., et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007, 13:122.
3. Watt K., Veldt B., Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009, 9:1707.
4. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889.
5. Melum E., Friman S., Bjoro K., Rasmussen A., Isoniemi H., Gjertsen H., et al. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. J Hepatol 2007, 47:777.
6. Coilly A., Roche B., Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013, 33(Suppl. 1):56.
7. Ackefors M., Nystrom J., Wernerson A., Gjertsen H., Sonnerborg A., Weiland O. Evolution of fibrosis during HCV recurrence after liver transplantation - influence of IL-28B SNP and response to peg-IFN and ribavirin treatment. J Viral Hepat 2013, 20:770.
8. Hornfeldt E., Gjertsen H., Weiland O. High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation. Scand J Infect Dis 2008, 40:259.
9. Angelico M., Petrolati A., Lionetti R., Lenci I., Burra P., Donato M.F., et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007, 46:1009.
10. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798.
11. Knapp S., Warshow U., Ho K.M., Hegazy D., Little A.M., Fowell A., et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology 2011, 141:320.
12. Mangia A., Thompson A.J., Santoro R., Piazzolla V., Copetti M., Minerva N., et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011, 54:772.
13. Tolmane I., Rozentale B., Keiss J., Ivancenko L., Subnikova N., Reinholde Z., et al. Interleukin 28B gene polymorphism and association with chronic hepatitis C therapy results in Latvia. Hepat Res Treat 2012, 2012:324090.
14. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338.
15. Antaki N., Bibert S., Kebbewar K., Asaad F., Baroudi O., Alideeb S., et al. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J Viral Hepat 2013, 20:59.
16. Lange C.M., Moradpour D., Doehring A., Lehr H.A., Mullhaupt B., Bibert S., et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011, 55:322.
17. Bitetto D., De Feo T., Mantovani M., Falleti E., Fabris C., Belli L.S., et al. Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. Dig Liver Dis 2013, 45:927.
18. Charlton M.R., Thompson A., Veldt B.J., Watt K., Tillmann H., Poterucha J.J., et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011, 53:317.
19. Eurich D., Boas-Knoop S., Bahra M., Neuhaus R., Somasundaram R., Neuhaus P., et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012, 93:644.
20. Gerlei Z., Sarvary E., Lengyel G., Gorog D., Fehervari I., Nemes B., et al. Measurement and clinical significance of interleukin 28B in hepatitis C virus-infected liver transplant patients. Transplant Proc 2012, 44:2154.
21. Firpi R.J., Dong H., Clark V.C., Soldevila-Pico C., Morelli G., Cabrera R., et al. CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int 2013, 33:72.
22. Coto-Llerena M., Perez-Del-Pulgar S., Crespo G., Carrion J.A., Martinez S.M., Sanchez-Tapias J.M., et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011, 11:1051.
23. Kawaoka T., Takahashi S., Takaki S., Hiramatsu A., Waki K., Hiraga N., et al. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol 2012, 27:1467.
24. Eurich D., Boas-Knoop S., Ruehl M., Schulz M., Carrillo E.D., Berg T., et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011, 17:289.
25. Fukuhara T., Taketomi A., Motomura T., Okano S., Ninomiya A., Abe T., et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139:1577.
26. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557.
27. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177.
28. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088.
29. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629.
30. Duarte-Rojo A., Veldt B.J., Goldstein D.D., Tillman H.L., Watt K.D., Heimbach J.K., et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012, 94:197.
31. Allam S.R., Kruger B., Mehrotra A., Schiano T., Schroppel B., Murphy B. The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation. PLoS One 2013, 8:e54854.
32. Crespo G., Carrion J.A., Coto-Llerena M., Marino Z., Lens S., Perez-Del-Pulgar S., et al. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol 2013, 48:762.
33. Coto-Llerena M., Crespo G., Gonzalez P., Koutsoudakis G., Miquel R., Navasa M., et al. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol 2012, 56:355.
34. Bellanti F., Vendemiale G., Altomare E., Serviddio G. The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Dev Immunol 2012, 2012:849373.
35. Luo Y., Jin C., Ling Z., Mou X., Zhang Q., Xiang C. Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. Gene 2013, 513:292.
36. Veldt B.J., Duarte-Rojo A., Thompson A.J., Watt K.D., Heimbach J.K., Tillmann H.L., et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant 2012, 12:737.
37. Pageaux G.P., Ducos J., Mondain A.M., Costes V., Picot M.C., Perrigault P.F., et al. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. Liver Transpl Surg 1997, 3:501.
38. Feray C., Caccamo L., Alexander G.J., Ducot B., Gugenheim J., Casanovas T., et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European concerted action on viral hepatitis (EUROHEP) group. Gastroenterology 1999, 117:619.
39. Donato M.F., Galmozzi E., Rigamonti C., Aghemo A. Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients. J Hepatol 2012, 56:1422.